Browsed by
Tag: biogerontology

An Open Letter to the Transhumanist Community – Article by Arin Vahanian

An Open Letter to the Transhumanist Community – Article by Arin Vahanian

Arin Vahanian


During the events that have transpired over the past few weeks, many of which have affected (and not in positive ways, sometimes) the USTP, Humanity+, and other organizations in the Transhumanism movement, I have mostly refrained from sharing my opinions and thoughts. However, I feel it is time now to share something that has been on my mind for a while.

But before I do so, I would like to express my disappointment at the level of discourse I am seeing in our community as a whole. Just a few days ago, the USTP released a statement condemning the vicious, vindictive manner in which someone in the Transhumanist community treated other members, as well as USTP Officers.

Instead of using this as a rallying cry for greater cooperation, an opportunity for increased self-awareness, as well as coordination on our shared goals, we now, yet again, have a candidate attacking another candidate, insulting their intelligence, not to mention their physical appearance.

Such petty, cruel behavior not only reflects negatively upon the person engaging in such behavior, but also reflects negatively on Transhumanism as a whole.

The sad truth of the matter, and what has been on my mind for a long while, but which I have been reluctant to share, is that many of the things that members of the general public dislike about Transhumanism, we have displayed here with great fervor, whether intentionally, or not.

Indeed, in some ways, we ourselves have become our worst enemies, treating each other with disdain, pretending that we are somehow more intelligent than others, disregarding the legitimate objections people have brought forward about the consequences of technology, ignoring how bizarre or unhinged some of our behaviors and actions may appear to the public, and being generally disconnected from the needs of the population as a whole.

However, it is not only a single candidate or person who is responsible for helping to create an environment in which arrogance, narcissism, unstable behavior, a lack of civility, pettiness, and a lack of empathy have persisted.

Sadly, we in the Transhumanist community are all responsible, because we have all allowed this sort of behavior to continue, over many months and many years. To be sure, this sort of behavior has been around long before this current USTP Presidential campaign started, but it continues, nonetheless.

One thing I have been passionate about and dedicated to from day one is to change the public’s perception of Transhumanism. To grow a movement that is small, into a worldwide force that is capable of great positive change, requires us to have a finger on the pulse of the views of the general public.

Vitriol is still vitriol, and venom is still venom, whether we sling it with bows and arrows, or whether we drop it like a bomb. We have no business complaining about the lack of civility in politics, in any country, when we ourselves are guilty of incivility. We should not lament the proliferation of cyberbullying when we ourselves engage in the same behavior.

We could say, once again, that the way we conduct ourselves in front of the general public influences greatly their opinions about Transhumanism, but this message has been nearly as ineffective as advocating for peace in the Middle East. We could say, once again, that we are a team, and that the shared goals we have are far more important than our disagreements with each other, but that doesn’t seem to have helped very much. We could say, once again, that humanity could benefit greatly from increased longevity, improved health, and the complete eradication of poverty, but even this, surprisingly, doesn’t seem to register with some people.

So let me put it this way, instead – the next time you think about hurling abuse at someone in our community, the next time you feel like getting even with someone for their past transgressions, consider the fact that in just a few decades, unless we achieve our objectives with anti-aging research and life extension, everyone here will likely be dead.

Dead, as in, they will no longer be able to hold a loved one in their arms. Dead, as in, they’ll never again feel the warm rays of the sun caressing their face on a summer morning. Dead, as in, they’ll never have the pleasure of tasting their favorite food again, or any food, for that matter.

In many ways, the movement has never been stronger. Transhumanism has been garnering more press coverage, thanks to the efforts of people like Zoltan Istvan. USTP membership has grown substantially in recent weeks and months, thanks to the leadership of Gennady Stolyarov. The work that pioneers such as Fereidoun Esfandiary (also known as FM-2030), Aubrey de Grey, Nick Bostrom, and Jose Cordeiro have done over decades has helped built the foundation for what we are able to do now.

Every time we attack each other, we dishonor the legacy the hard-working people in our movement have created. Every time we attack each other, it sets us back from important work we could be doing to help humanity with its greatest challenges.

Contrary to what some people may think, the work that Transhumanists are doing does not only benefit the Transhumanist community; it benefits people who don’t even know about us. It benefits people who are suffering from a rare disease and feel there is no light at the end of the tunnel. It benefits people who are struggling with crippling poverty, having to make a choice between starving to death or being homeless.

The indignation we may feel, righteous or not, at the lack of awareness and acceptance of our movement among the general public, isn’t the general public’s fault. It is simply because we have been unable, thus far, to clearly demonstrate, with a compassionate and unified voice, the many worthy and noble projects we are engaged in, as well as our vision, mission, and purpose. But there is no rule that says that this state of affairs has to continue.

Being able to demonstrate to the world the optimistic, humanitarian, and thoughtful goals of Transhumanism requires us to take a good look in the mirror and decide who we are, and who we want to be. But most importantly, it requires us to be optimistic, humanitarian, and thoughtful, ourselves. How we treat others is an indication, on some level, of how we look at the world as a whole.

Requesting that people be treated with respect, dignity, and kindness is not authoritarianism or fascism. It is called being a better human being. And one of the core tenets of Transhumanism is being a better human being. So let us start today, right now, by being better, not just to ourselves, but also to each other.

Arin Vahanian is Director of Marketing for the U.S. Transhumanist Party / Transhuman Party. 

Longevity Industry Systematized for First Time – Press Release by Biogerontology Research Foundation

Longevity Industry Systematized for First Time – Press Release by Biogerontology Research Foundation

Biogerontology Research Foundation


 

CREDIT: The Biogerontology Research Foundation, Deep Knowledge Life Sciences, Aging Analytics Agency and Longevity.International platform

Editor’s Note: Below is a press release by the Biogerontology Research Foundation on the longevity industry, which has been systematized for the first time in the report entitled The Science of Longevity. This press release was originally published here.

~ Dinorah Delfin, Director of  Recruitment, U.S. Transhumanist Party, February 5, 2018

Friday, Feb. 2, 2017, London, UK: The Biogerontology Research Foundation has embarked on a year-long mission to summarise in a single document the various emerging technologies and industries which can be brought to bear on aging, healthy longevity, and everything in between, as part of a joint project between The Global Longevity Consortium, consisting of the Biogerontology Research FoundationDeep Knowledge Life SciencesAging Analytics Agency and Longevity.International platform.

For scientists, policy makers, regulators, government officials, investors and other stakeholders, a consensus understanding of the field of human longevity remains fragmented, and has yet to be systematized by any coherent framework, and has not yet been the subject of a comprehensive report profiling the field and industry as a whole by any analytical agency to date. The consortium behind this series of reports hope that they will come to be used as a sort of Encyclopedia Britannica and specialized Wikipedia of the emerging longevity industry, with the aim of serving as the foundation upon which the first global framework of the industry will be built, given the significant industry growth projected over the coming years.

Experts on the subject of human longevity, who tend arrive at the subject from disparate fields, have failed even to agree on a likely order of magnitude for future human lifespan. Those who foresee a 100-year average in the near future are considered extreme optimists by some, while others have even mooted the possibility of indefinite life extension through comprehensive repair and maintenance. As such the longevity industry has often defied real understanding and has proved a complex and abstract topic in the minds of many, investors and governments in particular.

The first of these landmark reports, entitled ‘The Science of Longevity‘, standing at almost 800 pages in length, seeks to rectify this.

Part 1 of the report ties together the progress threads of the constituent industries into a coherent narrative, mapping the intersection of biomedical gerontology, regenerative medicine, precision medicine, artificial intelligence, offering a brief history and snapshot of each. Part 2 lists and individually profiles 650 longevity-focused entities, including research hubs, non-profit organizations, leading scientists, conferences, databases, books and journals. Infographics are used to illustrate where research institutions stand in relation to each other with regard to their disruptive potential: companies and institutions specialising in palliative technologies are placed at the periphery of circular diagrams, whereas those involved with more comprehensive, preventative interventions, such as rejuvenation biotechnologies and gene therapies, are depicted as central.

In this report great care was taken to visualize the complex and interconnected landscape of this field via state of the art infographics so as to distill the many players, scientific subsectors and technologies within the field of geroscience into common understanding. Their hope was to create a comprehensive yet readily-understandable view of the entire field and its many players, to serve a similar function that Mendeleev’s periodic table did for the field of chemistry. While these are static infographics in the reports, their creators plan to create complimentary online versions that are interactive and filterable, and to convene a series of experts to analyze these infographics and continually update them as the geroscience landscapes shifts. Similar strategies are employed in Volume II to illustrate the many companies and investors within the longevity industry.

These reports currently profile the top 100 entities in each of the categories, but in producing them, analysts found that the majority of these categories have significantly more than 100 entities associated with them. One of their main conclusions upon finishing the report is that the longevity industry is indeed of substantial size, with many industry and academic players, but that it remains relatively fragmented, lacking a sufficient degree of inter-organization collaboration and industry-academic partnerships. The group plans to expand these lists in follow-up volumes so as to give a more comprehensive overview of the individual companies, investors, books, journals, conferences and scientists that serve as the foundation of this emerging industry.

Since these reports are being spearheaded by the UK’s oldest biomedical charity focused on healthspan extension, the Biogerontology Research Foundation is publishing them online, freely available to the public. While the main focus of this series of reports is an analytical report on the emerging longevity industry, the reports still delve deeply into the science of longevity, and Volume I is dedicated exclusively to an overview of the history, present and future state of ageing research from a scientific perspective.

The consortium of organizations behind these reports anticipate them to be the first comprehensive analytical report on the emerging longevity industry to date, and hope to increase awareness and interest from investors, scientists, medical personnel, regulators, policy makers, government officials and the public-at-large in both the longevity industry as well as geroscience proper by providing a report that simultaneously distills the complex network of knowledge underlying the industry and field into easily and intuitively comprehensible infographics, while at the same time providing a comprehensive backbone of chapters and profiles on the various companies, investors, organizations, labs, institutions, books, journals and conferences for those inclined for a deeper dive into the vast foundation of the longevity industry and the field of geroscience.

It is hoped that this report will assist others in visualising the present longevity landscape and elucidate the various industry players and components. Volume 2, The Business of Longevity, which at approximately 500 pages in length aims to be as comprehensive as Volume 1, is set to be published shortly thereafter, and will focus on the companies and investors working in the field of precision preventive medicine with a focus on healthy longevity, which will be necessary in growing the industry fast enough to avert the impending crisis of global aging demographics.

These reports will be followed up throughout the coming year with Volume 3 (“Special Case Studies”), featuring 10 special case studies on specific longevity industry sectors, such as cell therapies, gene therapies, AI for biomarkers of aging, and more, Volume 4 (“Novel Longevity Financial System”), profiling how various corporations, pension funds, investment funds and governments will cooperate within the next decade to avoid the crisis of demographic aging, and Volume 5 (“Region Case Studies”), profiling the longevity industry in specific geographic regions.

These reports are, however, only the beginning, and ultimately will serve as a launching pad for an even more ambitious project: Longevity.International, an online platform that will house these reports, and also serve as a virtual ecosystem for uniting and incentivizing the many fragmented stakeholders of the longevity industry, including scientists, entrepreneurs, investors, policy makers, regulators and government officials to unite in the common goal of healthspan extension and aversion of the looping demographic aging and Silver Tsunami crisis. The platform will use knowledge crowdsourcing of top tier experts to unite scientists with entrepreneurs, entrepreneurs to investors, and investors to policy-makers and regulators, where all stakeholders can aggregate and integrate intelligence and expertise from each other using modern IT technologies for these types of knowledge platforms, and all stakeholders can be rewarded for their services.

 

The consortium behind these reports is interested in collaboration with interested contributors, institutional partners, and scientific reviewers to assist with the ongoing production of these reports, to enhance their outreach capabilities and ultimately to enhance the overall impact of these reports upon the scientific and business communities operating within the longevity industry, and can be reached at info@longevity.international

###

About the Biogerontology Research Foundation:

The Biogerontology Research Foundation is a UK non-profit research foundation and public policy center seeking to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF funds and conducts research which, building on the body of knowledge about how ageing happens, aims to develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age. Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of ageing, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.